The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulat
Novo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and speed up the expansion and diversification of products for serious chronic diseases.
